Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal group A and C conjugate vaccine (Mellowhope Pharmaceutical)
- Development stage
- Unknown
- Lead developer
- Mellowhope Pharmaceutical
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The meningococcal group A and C conjugate vaccine is a bivalent vaccine developed by Mellowhope Pharmaceutical (Shenzhen Mellowhope Pharm Industrial Co., Ltd.) for the prevention of invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A and C. This vaccine utilizes conjugation technology to chemically link the capsular polysaccharides of serogroups A and C to a carrier protein, which converts the T-cell independent polysaccharide antigens into T-cell dependent antigens. This process significantly improves the immune response, particularly in infants and young children, and induces long-term immunological memory. The vaccine is approved for use and is marketed under the Chinese name AC群脑膜炎球菌多糖结合疫苗.
- Other names
- AC群脑膜炎球菌多糖结合疫苗meningococcal A and C polysaccharide conjugate vaccinemeningococcal A and C conjugate vaccine
02
Targets
Neisseria meningitidis group C capsular polysaccharideNmA CPS (Neisseria meningitidis group A capsular polysaccharide)
Beyond the preview
Go deeper on meningococcal group A and C conjugate vaccine (Mellowhope Pharmaceutical).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal group A and C conjugate vaccine (Mellowhope Pharmaceutical).